Literature DB >> 28583016

A comparison of enriched culture and Xpert polymerase chain reaction assay of Group B streptococcus carrier status at 35-37-week gestation to labor onset: a prospective controlled study.

Yuri Perlitz1, Moshe Ben-Ami1, Emanuel C Megory2, Orna Nitzan3, Tal Bouganim1, Johnny S Younis1, Nora Shapso1, Avi Peretz4.   

Abstract

OBJECTIVES: (1) To compare the accuracy of vagino-rectal enriched culture (EC) and a rapid polymerase chain reaction (PCR) test for the detection of Group B streptococcus (GBS) carrier status at 35-37-week gestation and at onset of labor. (2) To assess the conversion rate of GBS carrier status between 35-37 weeks to the onset of labor according to the EC/PCR tests. A prospective study was performed at a women's health clinic, referred to give birth at one medical center. STUDY POPULATION: Low risk pregnant women at 35-37-week gestation who did not know their GBS carrier status.
METHODS: Participants were evaluated for GBS status both at 35-37 weeks and at labor onset. Correlation between tests was calculated by Spearman correlation.
RESULTS: One hundred and ten specimens were analyzed. Correlations: EC-PCR: 35-37 weeks - very high (r = 0.8), at labor - high (r = 0.5). EC-EC: 35-37 weeks and at labor - high (r = 0.39); PCR-PCR: 35-37 weeks and at labor- high (r = 0.7).
CONCLUSIONS: Both the EC and Xpert PCR tests are accurate for detecting GBS carrier, both at 35-37 weeks and at labor onset. We did not detect a significant conversion of the GBS status from negative at 35-37 weeks to positive at onset of labor.

Entities:  

Keywords:  GBS; PCR; carrier; culture; enriched; prenatal

Mesh:

Year:  2017        PMID: 28583016     DOI: 10.1080/14767058.2017.1338255

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  1 in total

1.  Clinical impact of rapid polymerase chain reaction (PCR) test for group B Streptococcus (GBS) in term women with ruptured membranes.

Authors:  Enya F Fullston; Michael J Doyle; Mary F Higgins; Susan J Knowles
Journal:  Ir J Med Sci       Date:  2019-01-31       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.